Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) Director Jens Holstein sold 5,000 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $40.95, for a total transaction of $204,750.00. Following the sale, the director owned 27,471 shares in the company, valued at $1,124,937.45. The trade was a 15.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Veracyte Trading Down 4.1%
Shares of Veracyte stock opened at $38.50 on Thursday. The company has a market cap of $3.10 billion, a PE ratio of 27.31 and a beta of 1.93. The company has a 50 day moving average of $48.01 and a 200-day moving average of $43.46. Veracyte, Inc. has a 1-year low of $29.45 and a 1-year high of $60.91.
Veracyte (NASDAQ:VCYT – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The business had revenue of $150.32 million during the quarter, compared to the consensus estimate of $144.59 million. Veracyte had a net margin of 20.37% and a return on equity of 9.26%. The company’s revenue was up 15.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.44 earnings per share. Research analysts forecast that Veracyte, Inc. will post 1.32 earnings per share for the current year.
Wall Street Analyst Weigh In
Read Our Latest Research Report on VCYT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new stake in Veracyte during the 2nd quarter worth approximately $44,000. Allworth Financial LP acquired a new position in shares of Veracyte during the second quarter worth $50,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Veracyte in the second quarter worth $62,000. GAMMA Investing LLC grew its stake in shares of Veracyte by 21.2% in the second quarter. GAMMA Investing LLC now owns 1,121 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 196 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in Veracyte during the 4th quarter worth $61,000.
About Veracyte
Veracyte, Inc is a diagnostics company that develops and commercializes genomic tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company combines genomic data with bioinformatics and machine-learning technologies to provide clinically actionable information from patient tissue samples.
Veracyte’s portfolio includes Afirma tests for evaluating thyroid nodules, Decipher tests for assessing the risk and biological characteristics of prostate cancer, and Prosigna for classifying and evaluating recurrence risk in certain breast cancers.
Read More
- Five stocks we like better than Veracyte
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
